PU files patents for green nanoplatform in skincare and pharma

Chandigarh: Panjab University has filed Indian and international patents for a new green nanomicelle platform developed by Professor Indu Pal Kaur and her PhD scholars Bakr Ahmed and Simrandeep Kaur.

The solvent-free, eco-friendly technology enables targeted delivery of sensitive bioactives such as peptides, herbal extracts, cannabinoids, vitamins, proteins, and small molecules.These components have applications in pharmaceuticals, nutraceuticals, cosmetics, paediatrics, veterinary care, and wellness products.

The platform is scalable and designed for clean-label processes, with formulations developed at room temperature. Minimal use of USFDA-approved solvents is allowed to accommodate poorly soluble actives without compromising safety or scalability. The technology has already been transferred to an industrial partner for skincare and cosmetics applications, marking a key step in academia-industry collaboration.

Professor Indu Pal Kaur, who leads the IPK Lab at Panjab University, described the innovation as affordable and adaptable, supporting both MSMEs and global companies in developing safe and sustainable products. Her lab focuses on turning research challenges into practical solutions, with a strong emphasis on long-term partnerships and technology transfer.
The university’s Centre for Industry-Institute Partnership Programme, established in 1996, plays a vital role in fostering innovation through revenue-sharing models between faculty and the institution.

Panjab University vice-chancellor Renu Vig said the university takes pride in translating research into industry-relevant innovations that improve lives and enhance its academic reputation.
With more than 22 patents granted and 17 filed, Professor Kaur’s work highlights the growing importance of intellectual property in India’s innovation ecosystem.

Related Posts

  • Pharma
  • July 16, 2025
  • 125 views
Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused…

  • Pharma
  • July 16, 2025
  • 40 views
Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

The pharma sector will be in focus on July 16, after Donald Trump said that pharmaceuticals tariffs would be implemented soon. Shares of pharmaceutical companies traded flat on Wednesday, July…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.